Author

Bin Xiang

Novartis (China)ORCID 0000-0002-9261-8347Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

Bisi Miao· 1 shared Chenxi HeiD· 1 shared En LiiD· 1 shared Fei LaniD· 1 shared Jia FaniD· 1 shared Jiabin CaiiD· 1 shared Jiajia CheniD· 1 shared Jian ZhouiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bisi Miao

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma

Bisi Miao, Ling Ge, Chenxi He, Xinghao Wang, Jibo Wu, Xiang Li, Kun Chen, Jinkai Wan, Shenghui Xing, Lingnan Ren, Zhennan Shi, Shengnan Liu, Yajun Hu, Jiajia Chen, Yanyan Yu, , Fei Lan

This study identifies SMYD5 as a methyltransferase that modifies RPL40 K22me3, enhancing translation and promoting hepatocellular carcinoma.

Cell Research · Aug 5, 2024Peer-reviewedCancer Biology